Dyne reports Q3 2026 results as z-rostudirsen BLA review continues toward January 2027 decisionNov 5Quarterly updateDyne Therapeutics
Dyne reports new one-year data from ACHIEVE trial of z-basivarsen in DM1Sep 29Clinical readoutDyne Therapeutics
Dyne reports Q2 2026 results as FDA accepts BLA for z-rostudirsenJul 29Quarterly updateDyne Therapeutics
Dyne Therapeutics prices upsized $375 million stock offering at $20.50 a shareJul 22FinancingDyne Therapeutics
VCU registers END-EXT natural history study for myotonic dystrophy type 1; Dyne, Vertex collaborateJul 13Trial updateDyne TherapeuticsVertex Pharmaceuticals Inc / Ma